169 related articles for article (PubMed ID: 24134216)
1. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment.
Venkatakrishnan K; Liu Y; Noe D; Mertz J; Bargfrede M; Marbury T; Farbakhsh K; Oliva C; Milton A
Br J Clin Pharmacol; 2014 Jun; 77(6):998-1010. PubMed ID: 24134216
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate renal impairment.
Venkatakrishnan K; Liu Y; Noe D; Mertz J; Bargfrede M; Marbury T; Farbakhsh K; Oliva C; Milton A
Br J Clin Pharmacol; 2014 Jun; 77(6):986-97. PubMed ID: 24134181
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic, pharmacodynamic, and electrocardiographic study of liposomal mifamurtide (L-MTP-PE) in healthy adult volunteers.
Venkatakrishnan K; Kramer WG; Synold TW; Goodman DB; Sides E; Oliva C
Eur J Clin Pharmacol; 2012 Oct; 68(10):1347-55. PubMed ID: 22460239
[TBL] [Abstract][Full Text] [Related]
4. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.
Anderson PM; Meyers P; Kleinerman E; Venkatakrishnan K; Hughes DP; Herzog C; Huh W; Sutphin R; Vyas YM; Shen V; Warwick A; Yeager N; Oliva C; Wang B; Liu Y; Chou A
Pediatr Blood Cancer; 2014 Feb; 61(2):238-44. PubMed ID: 23997016
[TBL] [Abstract][Full Text] [Related]
5. Mifamurtide: a review of its use in the treatment of osteosarcoma.
Frampton JE
Paediatr Drugs; 2010 Jun; 12(3):141-53. PubMed ID: 20481644
[TBL] [Abstract][Full Text] [Related]
6. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine.
Drugs R D; 2008; 9(2):131-5. PubMed ID: 18298131
[TBL] [Abstract][Full Text] [Related]
7. Mifamurtide in osteosarcoma--a practical review.
Anderson PM; Tomaras M; McConnell K
Drugs Today (Barc); 2010 May; 46(5):327-37. PubMed ID: 20517534
[TBL] [Abstract][Full Text] [Related]
8. Liposomal MTP-PE.
Gano JB; Kleinerman ES
J Pediatr Oncol Nurs; 1994 Oct; 11(4):161-3. PubMed ID: 7946146
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics of intravenous conivaptan in subjects with hepatic or renal impairment.
Roy MJ; Erdman KA; Abeyratne AT; Plumb LC; Lasseter K; Riff DS; Keirns JJ
Clin Pharmacokinet; 2013 May; 52(5):385-95. PubMed ID: 23456393
[TBL] [Abstract][Full Text] [Related]
10. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
[TBL] [Abstract][Full Text] [Related]
11. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.
Meyers PA
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1035-49. PubMed ID: 19671023
[TBL] [Abstract][Full Text] [Related]
12. Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience.
Taçyıldız N; Unal E; Dinçaslan H; Çakmak HM; Köse K; Tanyıldız G; Kartal Ö
Asian Pac J Cancer Prev; 2020 Mar; 21(3):715-720. PubMed ID: 32212798
[TBL] [Abstract][Full Text] [Related]
13. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.
Kubitza D; Roth A; Becka M; Alatrach A; Halabi A; Hinrichsen H; Mueck W
Br J Clin Pharmacol; 2013 Jul; 76(1):89-98. PubMed ID: 23294275
[TBL] [Abstract][Full Text] [Related]
14. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A.
Tanguay S; Bucana CD; Wilson MR; Fidler IJ; von Eschenbach AC; Killion JJ
Cancer Res; 1994 Nov; 54(22):5882-8. PubMed ID: 7954418
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
Murray JL; Kleinerman ES; Cunningham JE; Tatom JR; Andrejcio K; Lepe-Zuniga J; Lamki LM; Rosenblum MG; Frost H; Gutterman JU
J Clin Oncol; 1989 Dec; 7(12):1915-25. PubMed ID: 2479721
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency.
Tomlinson B; Thomas NG; Lan IW; Barbanoj M; Antonijoan RM; Drazna E; Ramis J; Obach R; Peraire C
Clin Pharmacokinet; 2006; 45(10):1003-11. PubMed ID: 16984213
[TBL] [Abstract][Full Text] [Related]
17. Comparative pharmacokinetics of free muramyl tripeptide phosphatidyl ethanolamine (MTP-PE) and liposomal MTP-PE.
Gay B; Cardot JM; Schnell C; van Hoogevest P; Gygax D
J Pharm Sci; 1993 Oct; 82(10):997-1001. PubMed ID: 8254500
[TBL] [Abstract][Full Text] [Related]
18. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Dayal S; Aluri J; Hall N; Filippov G; Moline M; Reyderman L; Landry I
Pharmacol Res Perspect; 2021 Apr; 9(2):e00758. PubMed ID: 33822479
[TBL] [Abstract][Full Text] [Related]
19. Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment.
Frost CE; Ly V; Garonzik SM
Drugs R D; 2021 Dec; 21(4):375-384. PubMed ID: 34363188
[TBL] [Abstract][Full Text] [Related]
20. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]